Optimi Health Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Dane Stevens
- Full Time Employees
- 9
- Sector
- Consumer Defensive
- Industry
- Agricultural Farm Products
- Address
- 1122 Mainland Street Vancouver BC Canada V6B 5L1
- IPO Date
- Apr 5, 2021
- Website
- optimihealth.ca
- Similar Companies
- Business
- Optimi Health Corp. Optimi Health Corp. (OTCQX: OPTHF) operates as a Health Canada-licensed, GMP-certified pharmaceutical manufacturer specializing in the production and supply of psychedelic substances and functional mushrooms for therapeutic research, clinical trials, and health and wellness applications. The company offers a range of core products including natural GMP-grade psilocybin and psilocin in raw biomass, extracts, capsules (such as 5mg standardized psilocybin capsules and 40mg/60mg MDMA capsules), active pharmaceutical ingredients (APIs), and finished drug products; functional mushroom supplements; and custom formulation services for researchers and licensed entities. It distributes these through online channels, Amazon marketplace, distributors, brokers, and exclusive partnerships like Mind Medicine Australia, targeting healthcare providers, pharmaceutical companies, clinical trial sponsors, and patients under regulated access programs primarily in Canada, Australia, and emerging U.S. markets. Founded in 2020 and headquartered in Garibaldi Highlands, British Columbia, Canada (with operations in Princeton), Optimi Health focuses on the psychedelic pharmaceuticals and wellness sectors, serving mental health treatment markets for conditions like treatment-resistant depression (TRD) and PTSD. In recent developments, the company launched psilocybin capsules in Australia under the Authorised Prescriber Scheme in September 2025, shipping 1,000 units following its 2024 MDMA export success, and secured inclusion in Medibank's AUD $10M psychotherapy program for TRD serving 4.2 million customers. Optimi received its U.S. FDA Establishment Identifier in 2025, enabling supply to authorized U.S. entities amid 25 states advancing psychedelic legislation, passed a Health Canada GMP inspection with no critical observations, filed an SEC registration for a proposed Nasdaq IPO under symbol OPTH, raised CAD $3.45M via convertible debentures, extended a CAD $1M term loan, and engaged MZ Investor Relations for capital markets support.
Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
SRx Health Solutions and EMJX Invest in Recent IPO and Commercial-Stage Pharmaceutical Company of Psychedelics, Optimi Health Corp. (OPTH)
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
Optimi Health schließt Psilocybin-Export nach Australien zur Behandlung therapieresistenter Depression ab
Optimi Health meldet Beginn der ersten MDMA-gestützten Behandlungen im Jahr 2026 in einem erweiterten Netzwerk australischer Kliniken
Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
Optimi Health (OTCMKTS:OPTHF) Trading 5.2% Higher – Still a Buy?
Optimi Health Announces Equity Incentive Grants and Corporate Update
Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026
Optimi Health (OTCMKTS:OPTHF) Trading Down 1.4% – What’s Next?
Optimi Health Announces Appointment of New Director
Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD
Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program
Optimi Health Announces Launch of Psilocybin Capsules in Australia for Treatment-Resistant Depression